Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.41 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26130780 | 0.79 | ALDH1A1 (0.48) | SMN1; SMN2KDM4EALDH1A1P4HTMNPC1 | |
| SCHEMBL13277846 | 0.79 | NPC1 (0.40) | MAPTCYP1A2KDM4EALDH1A1PARP10 | |
| SCHEMBL10328697 | 0.78 | CA1 (0.45) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL9852820 | 0.76 | KMT2A (0.40) | MAPTPLA2G4BCYP1A2ALDH1A1PARP10 | |
| SCHEMBL1403507 | 0.75 | P4HTM (0.63) | MAPTPLA2G4BCYP1A2KDM4EALDH1A1 | |
| SCHEMBL9477821 | 0.74 | NPC1 (0.47) | MAPTSMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL12614887 | 0.73 | NQO1 (0.48) | MAPTCYP1A2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL13278170 | 0.72 | NQO1 (0.38) | MAPTSMN1; SMN2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL15908848 | 0.72 | KDM4E (0.42) | MAPTPLA2G4BSMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL8785751 | 0.72 | KDM4E (0.45) | MAPTPLA2G4BSMN1; SMN2CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665732-B1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-2665732-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-8592408-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| WO-2012098213-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-0444286-A1 | Sulphonylated pyrimidine carboxylic acid amides | BAYER AG (DE) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPT 11/4885PLA2G4B 3559/4885SMN1; SMN2 925/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPT 11/4885PLA2G4B 3559/4885SMN1; SMN2 925/4885 |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | MAPT 11/4885PLA2G4B 3559/4885SMN1; SMN2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.